TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Half-Dose Radiopharmaceutical in Wide Beam Reconstruction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over the age of 18 years~* Undergoing nuclear stress testing~* History of myocardial infarction, cardiomyopathy, heart failure or prior nuclear studies with resting perfusion defects~Exclusion Criteria:~* Unwilling or unable to undergo an additional resting SPECT acquisition~* Clinical contraindications to nuclear stress testing including acute myocardial infarction~  * For patients undergoing exercise treadmill stress testing:~* Left bundle branch block or artificial ventricular pacemaker~  * For patients undergoing regadenoson (Lexiscan) stress testing:~* Moderate to severe chronic obstructive pulmonary disease or asthma, second- or third degree atrioventricular block or sinus node disease (unless patients have a functioning artificial pacemaker), known hypersensitivity to aminophylline or adenosine~* Inability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Half-dose radiotracer administration (Type: EXPERIMENTAL): For this study, researchers would like to administer half of the radiotracer, obtain resting images, administer the remainder of the radiotracer and obtain a second set of resting images. Subjects will be given the same amount of radioactive material that would normally be given for this test; however, it will be administered in two ½ doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: DirectVision for Urinary Catheterization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any patient over 18 years with a standard indication for difficult urinary catheterization~Exclusion Criteria:~* Any patient younger than 18 years of age, pregnant patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Cystoscopy (Type: ACTIVE_COMPARATOR): will have catheter placement using the cystoscopy method
- DirectVision (Type: ACTIVE_COMPARATOR): will have catheter placement using DirectVision.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Gestational age at birth 23 0/7 to 27 6/7 weeks by best obstetrical dating~2. No previous exposure to indomethacin~3. Clinical determination to use indomethacin to attempt closure of PDA~4. No known congenital abnormalities involving the kidneys, heart or lungs~5. No preexisting renal dysfunction, defined as serum creatinine \> 1.0 mg/dl, or urine output \<1.0 ml/kg/hour over the previous 24 hours.~Exclusion Criteria:~1. Enrollment in concurrent study in which interventions may contribute confounding variables or have competing outcomes~2. Infants with antenatally or postnatally diagnosed renal or urinary tract abnormalities~3. Infants with umbilical cord or infant blood pH below 7.0 at any time before enrollment~4. Attending physician unwilling to have infant participate in study~5. Absence of informed consent

- Gender: ALL
- Minimum Age: 0 Days
- Maximum Age: 28 Days
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Infants in the Placebo arm will receive 0.9% sodium chloride (0.1 ml/hr). If, after 6 hrs there is not a clinically concerning decrease in blood pressure, as determined by attending physician, the rate of infusion (in this arm the placebo) will be increased to 0.2 ml/kg/hr. This rate will be continued throughout the remainder of the study.
- Fenoldopam (Type: EXPERIMENTAL): Infants in the experimental arm will receive fenoldopam (60 ug/ml; 0.1 ml/hr to provide 0.1ug/kg/min). If, after 6 hrs there is not a clinically concerning decrease in blood pressure, as determined by attending physician, the rate of infusion will be increased to 0.2 ml/kg/hr (0.2 ug/kg/min for infants receiving fenoldopam). This rate will be continued throughout the remainder of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Caudal Blockade and Electrocardiographic Changes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* ASA grade 1 or 2~* Receiving general anesthesia with a caudal block~Exclusion Criteria:~* Preexisting cardiac comorbidities

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Caudal block (Type: None): Patients that receive regional anesthesia in the form of a caudal block prior to surgery as part of their standard of care.
- Control (Type: None): Patients who do not receive a caudal block.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Sedation Versus No Sedation in a Spontaneous Breathing Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult age 18 or older~* Intubation time greater than or equal to 24 hours~* Patient is sedated at the time the MICU writes the order for the SBT. A RASS score of less than -2 will be considered sedated~Exclusion Criteria:~* Acute brain injury~* Pregnancy~* Wards of the state

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Sedation suring a spontaneous breathing trial.
- 2 (Type: OTHER): No sedation during spontaneous breathing trial

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antero-posterior Versus Antero-lateral Electrode Position for Electrical Cardioversion of Typical Atrial Flutter

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* clinical diagnosis of typical atrial flutter~* signed written informed consent~* eligibility for sedation and external electrical cardioversion~Exclusion Criteria:~* clinical diagnosis of arrhythmia other than typical atrial flutter~* implanted ICD or pacemaker~* proof of atrial thrombi

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AP Position (Type: ACTIVE_COMPARATOR): Cardioversion with antero-posterior electrode position
- AL Position (Type: ACTIVE_COMPARATOR): Cardioversion with antero-lateral electrode position

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. \> 18 years of age~2. Signed Informed Consent~3. Subjects diagnosed with Primary Pulmonary Hypertension or Myelofibrosis (primary or secondary)~Exclusion Criteria:~1. Anyone not meeting the above inclusion criteria~2. Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PPH (Type: None): Subjects diagnosed with primary pulmonary hypertension (PPH)
- Myelofibrosis (Type: None): Subjects diagnosed with Primary or Secondary Myelofibrosis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Apotransferrin in Patients With β-thalassemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Non-transfusion dependent β-thalassemia intermedia, defined as patients with microcytic anaemia in combination with an elevated HbA2 (\>2.5%) and a haemoglobin of \<6.2 mmol/L, or transfusion dependent β-thalassemia treated with a regular transfusion schedule.~* Age above≥ 17 years.~* Adequate renal and hepatic function tests~* WHO performance 0, 1 or 2.~* Signed informed consent.~Exclusion Criteria:~* Known with allergic reactions against human plasma or plasma products.~* Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension, pulmonary disease).~* Cardiac dysfunction as defined by: myocardial infarction within the last 6 months of study entry, unstable angina, or unstable cardiac arrhythmias.~* Pregnant or lactating females.~* Known with IgA deficiency with anti-IgA antibodies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- human apotransferrin (Type: EXPERIMENTAL): Patients will receive an intravenous dose of human apotransferrin every two weeks for 14-18 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Identifying Pain Generators and Potentiators of Residual Complaints Following Lumbar Discectomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Dutch speaking~* Body mass index below 35kg/m²~* Lumbar radiculopathy patients, classified as ASA I to II without any symptoms of spinal cord compression (i.e. bilateral leg pain), who are scheduled for a first-time, single-level, unilateral lumbar discectomy~* Healthy, pain-free controls (score 0 on a visual analogue scale from 0 to 100)~Exclusion Criteria:~* Female participants will be excluded if pregnant, lactating or \<1 year postnatal~* Having (a history) of severe medical disorders either respiratory (e.g. cystic fibrosis), orthopedic (e.g. whiplash trauma), neurologic (e.g. cerebrovascular incident), cardiovascular (e.g. severe hypertension), endocrinological (e.g. diabetes), psychiatric (e.g. post-traumatic stress disorder~* Having a history of spinal surgery (e.g. discectomy), spinal traumata (e.g. vertebral fracture) or severe spinal deformities (e.g. spondylolisthesis)~* Having a pacemaker or defibrillator~* Healthy controls will be excluded if having suffered low back pain in the preceding year of score 2 or higher on the visual analog scale and which limited their activities of daily living or for which they consulted a (para)medic.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Lumbar radiculopathy (Type: None): Lumbar radiculopathy patients (n=122), classified as ASA I to II without any symptoms of spinal cord compression (i.e. bilateral leg pain), who are scheduled for a first-time, single-level, unilateral lumbar discectomy.
- Healthy controls (Type: None): Sex, age, and BMI-matched healthy, pain-free control subjects (n=122) will be recruited for study participation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent~* Male or female \> 18 years of age~* Histologically proven GCT treated with surgery~* High risk GCT defined as minimal one or more of the following:~  * Recurrent GCT~ * GCT located in the pelvis, sacrum, spine, distal ulna or growth in soft tissue~ * GCT grade III~ * Pathological fracture in GCT~ * Absence of local adjuvant therapy (cryosurgery or phenol instillation)~* Neutrophils \> 1.5x109/L, platelets \> 100x109/L, and Hb \> 6 mmol/l~* Bilirubin level \< 1.5 x ULN~* ASAT and ALAT \< 2.5 x ULN~* Adequate renal function as defined by: serum creatinine clearance \> 60 cc/min~* Expected adequacy of follow-up~Exclusion Criteria:~* Unresectable or metastatic GCT and grade IV GCT~* Prior bisphosphonate usage, except preoperative treatment with zoledronic acid up to 3 months before surgery~* Other previous malignancy within 5 years, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix~* Known hypersensitivity reaction to any of the components of the treatment~* Pregnancy or lactating~* Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zoledronic acid (Type: EXPERIMENTAL): Adjuvant zoledronic acid
- Control (Type: NO_INTERVENTION): Standard care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Chronic Hepatitis C (CHC) - Genotype 3 Infection in Canada

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Infected with only genotype 3, hepatitis C~* Treatment naïve before current course of therapy~* Age 18 or older~Exclusion Criteria:~* Under age 18~* Co-infection with HIV or Hepatitis B or any other HCV genotype in addition to genotype 3~* Prior treatment for Hepatitis C aside from herbal remedies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Indwelling Pleural Catheter With Either Doxycycline or Saline at Day 7 for Pleurodesis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Outpatients with MPE undergoing IPC placement~2. Age 18 or older~3. Sufficient mental capacity to answer SF-6D and Borg score questions.~Exclusion Criteria:~1. Patients undergoing pleurodesis for benign disease (e.g., spontaneous pneumothorax)~2. Inability or unwillingness to give informed consent~3. Inability to perform phone call and clinical follow-up at MDACC~4. Previous intrapleural therapy for MPE on the same side~5. Chylous effusions associated with malignant disease~6. ECOG of 4 and life expectancy \</= 2 weeks~7. Doxycycline allergy~8. Contraindication to placement of an IPC (e.g., uncorrected coagulopathy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indwelling Pleural Catheter (IPC) + Saline (Type: EXPERIMENTAL): Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Saline. Participant given a Fentanyl patch which should be worn at follow up visit 5 days after IPC placement. Fentanyl patch then be removed and Fentanyl by vein given prior to catheter draining. Study staff drains the IPC and places Saline in the catheter.~After the IPC is removed, participant is called one time each month by study staff to check on their status.
- Indwelling Pleural Catheter (IPC) + Doxycycline (Type: ACTIVE_COMPARATOR): Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Doxycycline. Participant given a Fentanyl patch which should be worn at follow up visit 5 days after IPC placement. Fentanyl patch then be removed and Fentanyl by vein given prior to catheter draining. Study staff drains the IPC and places Doxycycline in the catheter.~After the IPC is removed, participant is called one time each month by study staff to check on their status

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Buprenorphine on Ulnar Nerve Motor Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Male~2. Age: 18 - 65 years~3. Weight: 50-100kg~4. Height: 155-195cm~5. Signed and dated informed consent~6. Sufficient command of German language~Exclusion Criteria:~1. Contraindications to the class of drugs under study~2. Vulnerable subjects (intellectually or mental impaired)~3. Known hypersensitivity to class of drugs or the investigational product~4. Drug abuse~5. Known peripheral neuropathies~6. Diabetes mellitus~7. Chronic alcohol consumption~8. Congestive heart disease~9. Participants of other studies during study period

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~The current Study will involve analysis of existing samples (DNA, serum, cells, plasma) and data. The entire set of 333 subjects in the HGDS cohort will be analyzed.~EXCLUSION CRITERIA:~No subjects will be excluded from the HGDS cohort.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Induced Hypertension for Delayed Cerebral Ischaemia After Aneurysmal Subarachnoid Haemorrhage:a Feasibility Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Admission to the UMC Utrecht.~2. Age 18 years or over.~3. Aneurysmal SAH, demonstrated on CT-angiography or cerebral angiography, with onset less than 72 hours before admission.~4. A level of consciousness corresponding to a Glasgow Coma Sum Score above 8, as in patients with lower Glasgow Coma Sum Scores, assessment of further deterioration may be less reliable.~Exclusion Criteria:~1. Symptomatic aneurysm not yet treated by coiling or clipping. Co-existing asymptomatic cerebral aneurysms are no reason for exclusion, since previous studies found no increased risk of rupture of such aneurysms during hypertensive and hypervolemic treatment.(26)~2. Co-existing severe head injury.~3. A history of a cardiac rhythm disorder, necessitating medical treatment.~4. A history of a left ventricular pump failure, necessitating medical treatment.~5. Pregnancy.~6. Known allergy for CT-contrast agents.~7. Renal failure, defined as a serum creatinine \> 150 µmol/l, because of the risk of contrast nephropathy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: NO_INTERVENTION): No induced hypertension (reference group)
- 2 (Type: EXPERIMENTAL): Induced hypertension with a MAP of 30 mmHg above the average MAP on the previous day; during 24-36 hours, until a perfusion CT scan has been performed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility